GenScript will launch services with GANP® technology for World Wide market excluding Japan
Mar 22, 2011
Piscataway, New Jersey, Mar 23rd, 2010 - GenScript Corporation signed a worldwide (excluding Japan) non-exclusive license agreement with TransGenic Inc. through which GenScript Corporation is authorized to use GANP® mice from TransGenic Inc. to produce high-affinity antibodies to scientists.
GANP (Germinal Center Associated Nuclear Protein) is a protein discovered by Dr. Nobuo Sakaguchi at Kumamoto University to be over-expressed in B-cells centered in embryo. Research suggested that GANP is important in the reconstruction of antibody genes. Transgenic mice which express high level of GANP can be used to produce antibodies with a high affinity.
“This technology will tremendously improve the quality of our antibody products in terms of specificity, affinity and epitope diversity.” commented David Chang, director of GenScript’s Antibody Department.
GenScript has developed a state-of-the-art antibody production platform to meet different customers' needs, including OptimumAntigenTM design tool, T-MaxTM adjuvant, and nanotechnology for antigen preparation. Her animal facility was accredited by AAALAC and OLAW. With access to GANP® Mouse Technology, antibodies generated from GenScript can potentially be used for diagnostic and therapeutic purposes because of higher affinity and higher specificity.
About GenScript Corporation
GenScript is a contract research organization (CRO) specialized in biological research and early-phase drug discovery services. Its service portfolio includes bio-reagent services, assay development & screening, lead optimization, and antibody drug development. The renowned one-stop bioreagent services include custom gene synthesis and molecular biology, custom protein expression and purification, custom peptide synthesis, antibody production, and custom cell line development. Headquartered in Piscataway, New Jersey, GenScript is the largest gene synthesis supplier in the USA, with subsidiaries in France, Japan, and China.
# # # #
For further information, please contact:
Executive Vice President
GENSCRIPT USA Inc.
Your Innovation Partner in Drug Discovery!